Dimethyl fumarate Teva Unia Europejska - duński - EMA (European Medicines Agency)

dimethyl fumarate teva

teva gmbh - dimethylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Dimethyl fumarate Accord Unia Europejska - duński - EMA (European Medicines Agency)

dimethyl fumarate accord

accord healthcare s.l.u. - dimethylfumarat - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressiva - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Kexxtone Unia Europejska - duński - EMA (European Medicines Agency)

kexxtone

elanco gmbh - monensin (som monensinnatrium) - lægemidler til forebyggelse og/eller behandling af acetonemia - kvæg (køer og kvier) - for reduktionen i forekomsten af ​​ketose i den peri-parturiente malkeko / kvier, som forventes at udvikle ketose.

Sitagliptin / Metformin hydrochloride Mylan Unia Europejska - duński - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - narkotika anvendt i diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trepersoners-kombinationsbehandling) som supplement til diæt og motion hos patienter, der ikke er tilstrækkeligt kontrolleret på deres maksimal tolereret dosis af metformin og et sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Cilest 250 + 35 mikrogram filmovertrukne tabletter Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

cilest 250 + 35 mikrogram filmovertrukne tabletter

janssen-cilag a/s - ethinylestradiol, norgestimat - filmovertrukne tabletter - 250 + 35 mikrogram

Cilest 250+35 mikrogram tabletter Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

cilest 250+35 mikrogram tabletter

orifarm a/s - ethinylestradiol, norgestimat - tabletter - 250+35 mikrogram

Minero 75 + 20 mikrogram overtrukne tabletter Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

minero 75 + 20 mikrogram overtrukne tabletter

orifarm generics a/s - ethinylestradiol, gestoden - overtrukne tabletter - 75 + 20 mikrogram

Modina 75+30 mikrogram overtrukne tabletter Dania - duński - Lægemiddelstyrelsen (Danish Medicines Agency)

modina 75+30 mikrogram overtrukne tabletter

orifarm generics a/s - ethinylestradiol, gestoden - overtrukne tabletter - 75+30 mikrogram